Douglas Fuller

Douglas Fuller is an experienced biostatistician currently serving as the Associate Director of Biostatistics at Jazz Pharmaceuticals, focusing on Medical Affairs and Value Biostatistics since March 2021. In this role, Douglas is the Global Lead for the Sleep therapeutic area and previously led efforts for Epidiolex/Epidyolex. Prior to this position, Douglas worked at PRA Health Sciences as a Senior Biostatistician, where responsibilities included leading multiple Phase I, IV, and real-world evidence studies in neurology and oncology. Douglas’s earlier experience includes a Senior Research Analyst II position at Arbor Research Collaborative for Health, providing analytical support for international hemodialysis studies, and serving as the Section Chair for Alpha Phi Omega. Douglas holds a Master’s degree in Biostatistics from the University of Michigan at Ann Arbor and a Bachelor’s degree in Computer Science from the University of Illinois Urbana-Champaign.